Inherited Cancer Registry (ICARE)’s Post

Today we shine a spotlight on Lake Macquarie Private Hospital (LMPH) Clinical Trials Unit, a pivotal site in our network of 20 clinical trial sites nationwide. Managed and led by Hollie Ritchie, this unit drives research across diverse therapeutic areas including oncology, cardiology, neurology, and orthopaedics. Read about one of the current trials conducted at LMPH, the BRCA-P Trial, an international breast cancer prevention trial testing the effectiveness of a drug called ‘Denosumab’ to decrease or prevent the risk of developing breast cancer in women who carry a BRCA1 gene mutation.   If you’re interested in being a part of clinical trials at LMPH or need more information, please reach out to the team at [email protected] #ramsaayhealthcare #clinicaltrials #LMPH #peoplecaringforpeople #research #researchatramsay #ramsayresearch https://lnkd.in/gdD_K_wE

🚨 Breast cancer is the leading cause of death in women aged 35-49, with 1 in 7 women likely to develop the disease in their lifetime according to Against Breast Cancer research. When we’re faced with statistics as black and white as this, it’s a reminder that there’s a desperate need for innovative approaches to #cancer treatment. Innovative approaches that help reduce the strain on resources, enhance the patient experience and, ultimately, provide better outcomes for those going through treatment. Our easy to use at-home blood monitoring system, #Liberty, allows us to capture advanced data so healthcare systems can manage cancer treatment effectively. Designed to monitor and prevent treatment side effects, such as febrile neutropenia, from escalating into life-threatening complications, keeping patients on their treatment plans for longer, and improving their overall outcome. 💡 Interested in seeing how Liberty can make a difference? Book a demo by sending us a DM 👇🏽 https://lnkd.in/eWr42WMA #BreastCancerAwareness #CancerCare #RemotePatientMonitoring #Oncology #Healthcare #nhs #Innovation #WomensHealth #Innovation #DataAnalytics

Interesting study - in keeping with our previous findings that down-regulation of PTEN contributes to CAF formation and senescence - but how?  https://lnkd.in/evxah4m3

What new evidence and methodology did our Working Group consider in its re-evaluation of the carcinogenicity of talc? Read about it below ⬇️

🎯 Atricle#3. Identification and characterization of small molecule inhibitors of the LINE-1 retrotransposon endonuclease. The long interspersed nuclear element-1 (LINE-1 or L1) retrotransposon is the only active autonomously replicating retrotransposon in the human genome. L1 harms the cell by inserting new copies, generating DNA damage, and triggering inflammation. Therefore, L1 inhibition could be used to treat many diseases associated with these processes. Previous research has focused on inhibition of the L1 reverse transcriptase due to the prevalence of wellcharacterized inhibitors of related viral enzymes. Here we present the L1 endonuclease as another target for reducing L1 activity. We characterize structurally diverse small molecule endonuclease inhibitors using computational, biochemical, and biophysical methods. We also show that these inhibitors reduce L1 retrotransposition, L1-induced DNA damage, and inflammation reinforced by L1 in senescent cells. These inhibitors could be used for further pharmacological development and as tools to better understand the life cycle of this element and its impact on disease processes. Full article is available here https://lnkd.in/dAzcTnzZ #drugdiscovery #smallmolecules  #inhibitors #research #biotech #medicinalchemistry #drugspharmaceuticals #hitcompound #bioactivity #pharmaceuticalsciences #treatment #diseasetreatment #biotech #research #targets #leadgeneration #cancer #cancertherapy #Cancertarget #cancertreatment #alzheimersdisease #newmedicine #immunotherapy #infectiousdiseases 

Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets. In recent years, several monoclonal antibodies (mAbs) targeting PD-L1 have been licensed by the FDA for use in the treatment of cancer, demonstrating the effectiveness of blocking immune checkpoints, particularly the PD-1/ PD-L1 pathway. Although mAb-based therapies have made great strides, they still have their limitations, and new small-molecule or PROTAC-molecule inhibitors that can block the PD-1/PD-L1 axis are desperately needed. Therefore, it is crucial to translate initial in vitro discoveries into appropriate in vivo animal models when creating PD-L1-blocking therapies. Due to their widespread availability and low experimental expenses, classical immunocompetent mice are appealing for research purposes. However, it is yet unclear whether the mouse (m) PD-L1 interaction with human (h) PD-1 in vivo would produce a functional immunological checkpoint. In this review, authors summarize the in vitro and in vivo experimental studies of small molecules and PROTAC molecules, particularly the distinctions between mPD-L1 as a target and hPD-L1 as a target. Full article is here https://lnkd.in/dnqSVphU #drugdiscovery #smallmolecules  #inhibitors #research #biotech #medicinalchemistry #drugspharmaceuticals #hitcompound #bioactivity #pharmaceuticalsciences #treatment #PROTAC #Peptidedegradation #Molecularglue #diseasetreatment #biotech #research #targets #leadgeneration

🐁 Today's JAX Poster Presentations topics at AACR from 1:30-5 p.m., PT, include: • Mouse models advancing cancer research • The mouse models of human cancer database (MMHCdb) • Modeling individual variability in CD19 CAR-T therapy: An in vivo study with PBMC-humanized mice • Accelerated intra-clonal transcriptomic diversification of hematopoietic stem cells during aging fuels leukemia evolution • Spatial proteomics of lung adenocarcinoma mouse models with divergent propensities for metastasis • Spatial immunology landscapes that correlate with survival in triple negative breast cancer https://lnkd.in/exe9h3kU

Want to learn more about the Future of Cell Gene Therapy? Listen to this Podcast with McKesson's Joe DePinto!"

mTPI study design for oncology phase 1 studies: a practical approach for the Medical Director and Clinical Scientist. Enjoy 28 minutes of teaching, and tell us what you want to see next. https://lnkd.in/gBmMxcpD

The 'Cancer Survivorship - AI for Well Being' Cluster Recently at the Champalimaud Foundation (Lisbon), May 2024, it was an honour to present the work of the 'Cancer Survivorship - AI for Well Being' #cluster (www.cs-aiw.eu), which presently involves twelve European #scientific #research projects centred around the quality of life (#QoL) and well-being care in the post-cancer patient treatment space, appropriately supported and includes #AI and #smartechnology. See .. https://lnkd.in/ePMQ8wdX New European scientific related projects in the cancer survivorship space are always welcomed to join. Our initial contact point is through email i.e., [email protected]. #Cancer, #Cancersurvivorship, #mhealth, #ehealth, #scientificresearch, #Europe www.cs-aiw.eu www.tfcengage.com